INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426594, 'Orciprenaline', 'Nadolol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426595, 'Nadolol', 'Methacholine', 'Major', 'Patients who are concurrently receiving beta blockers may have exaggerated or prolonged responses (i.e., bronchoconstriction) to methacholine challenge and may not respond readily to treatment. Beta-2-adrenergic blockade increases airway resistance. Ophthalmically applied beta blockers undergo some systemic absorption and potentially may also interact.', NULL, 'Administration of methacholine to a patient on any beta blocker therapy is considered contraindicated.', NULL, 'Administration of methacholine to a patient on any beta blocker therapy is considered contraindicated.', 'Others', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426596, 'Bendroflumethiazide', 'Methotrexate', 'Moderate', 'Antineoplastic-induced bone marrow suppression may be prolonged with concomitant thiazide administration. The mechanism is unknown. Thiazides have been associated with blood dyscrasias.', NULL, 'Alternative antihypertensive therapy may be advisable.', NULL, 'Alternative antihypertensive therapy may be advisable. Hematological status should be closely monitored in patients receiving this combination.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426597, 'Nadolol', 'Methoxyflurane', 'Moderate', 'The antihypertensive effects of methoxyflurane and beta blockers may be additive. The combination may cause profound hypotension. Older anesthetics such as methoxyflurane have more severe circulatory depressant effects in the presence of beta-blockade.', NULL, 'It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery.', NULL, 'It is currently recommended that beta blocker therapy not be routinely withdrawn prior to surgery. However, in general, patients taking beta blockers should not be anaesthetized with methoxyflurane. Instead, an anesthetic with minimal negative inotropic activity may be considered. If methoxyflurane must be used, beta blocker therapy should be withdrawn gradually and generally completed 24 to 48 hours before anesthesia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426598, 'Nadolol', 'Methylergometrine', 'Moderate', 'Several case reports have suggested that beta-blockers may potentiate the vasoconstrictive action of ergot alkaloids. The exact mechanism of interaction is unknown, but may involve blockade of beta-2-mediated (i.e., sympathetic) vasodilatation. In addition, beta-1 blockade reduces cardiac output, which can diminish blood flow and exacerbate ergot-induced vasospasm.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary.', NULL, 'Except for increased awareness of the interaction, no specific intervention appears to be necessary. Patients should be advised to seek immediate medical attention if they experience potential symptoms of ischemia such as coldness, pallor, cyanosis, numbness, tingling, or pain in the extremities; muscle weakness; severe or worsening headache; visual disturbances; severe abdominal pain; chest pain; and shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426599, 'Nadolol', 'Methylprednisolone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426600, 'Nadolol', 'Metipranolol (ophthalmic)', 'Moderate', 'Ophthalmic beta blocker solutions are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Additive effects of beta blockade may occur in patients receiving both oral and ophthalmic beta blocking agents.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use.', NULL, 'Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426601, 'Nadolol', 'Metolazone', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426602, 'Nabumetone', 'Nadolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426603, 'Naproxen', 'Nadolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426604, 'Neostigmine', 'Nadolol', 'Moderate', 'Severe bradycardia and hypotension may develop during concomitant administration of some beta-blockers and anticholinesterase agents. The mechanism is unknown but may involve additive effects.', NULL, 'The patient''s hemodynamic status should be monitored during coadministration.', NULL, 'The patient''s hemodynamic status should be monitored during coadministration. Patients should be advised to notify their physician if they experience syncope, orthostasis, or a slow pulse.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426605, 'Nicardipine', 'Nadolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426606, 'Nimodipine', 'Nadolol', 'Moderate', 'Additive reductions in heart rate, cardiac conduction, and cardiac contractility may occur when calcium channel blockers are used concomitantly with beta blockers, particularly in patients with ventricular or conduction abnormalities. While this combination may be useful and effective in some situations, potentially serious cardiovascular adverse effects such as congestive heart failure, severe hypotension, and/or exacerbation of angina may occur. The proposed mechanisms include additive slowing in AV conduction, reduced cardiac contractility secondary to beta-blockade, and decreased peripheral vascular resistance secondary to calcium channel blockade. In addition, some calcium channel blockers may inhibit the CYP450 metabolism of hepatically metabolized beta blockers, resulting in increased serum concentrations.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary.', NULL, 'Close clinical monitoring of patient hemodynamic response and tolerance is recommended if a calcium channel blocker is prescribed with a beta blocker, and the dosage of one or both agents adjusted as necessary. The same precaution should be observed when beta blocker ophthalmic solutions are used, since they are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', 'Metabolism, Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426607, 'Norepinephrine', 'Nadolol', 'Moderate', 'Beta-blockers may antagonize the cardiostimulatory effects of pressor agents by blocking beta-1 adrenergic receptors in the heart. Vasopressors may be less effective if the patient is receiving, or has recently received, a beta-blocking drug. In addition, peripheral vascular resistance may increase due to unopposed alpha-adrenergic effects of pressor agents in the presence of beta-blockade. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations.', NULL, 'No specific intervention is necessary, but clinicians should be alert to the potential for diminished cardiac response when pressor agents are used in patients treated with beta-blockers, including ophthalmic formulations. A beta-blocker such as propranolol may be used to treat cardiac arrhythmias that occur during administration of pressor agents like mephentermine, metaraminol, norepinephrine, or phenylephrine.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426608, 'Nortriptyline', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426609, 'Octreotide', 'Nadolol', 'Moderate', 'Somatostatin analogs (e.g., octreotide, lanreotide) can decrease heart rate and may potentiate the bradycardic effects of drugs like beta-blockers, calcium channel blockers, digitalis glycosides, and certain antiarrhythmic agents (e.g., class I antiarrhythmics, adenosine, amiodarone).', NULL, 'Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers.', NULL, 'Caution is advised if somatostatin analogs are prescribed with agents that exhibit bradycardic effects, including ophthalmic formulations of beta-blockers. Heart rate and blood pressure should be monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426610, 'Oliceridine', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426611, 'Olodaterol', 'Nadolol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426612, 'Oxazepam', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426613, 'Oxtriphylline', 'Nadolol', 'Major', 'The pharmacologic effects of theophyllines and beta-blockers are opposite. Nonselective and high doses of cardioselective beta-blockers may cause severe or fatal bronchospasm by opposing theophylline-induced bronchodilation. Ophthalmic beta-blockers undergo significant systemic absorption and may also interact. In addition, propranolol and other beta-blockers may reduce the CYP450 hepatic metabolism of theophylline, and serum theophylline levels may be increased.', NULL, 'Oral and ophthalmic nonselective beta-blockers (e.', NULL, 'Oral and ophthalmic nonselective beta-blockers (e.g., carteolol, carvedilol, levobunolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol) are considered contraindicated in patients with bronchospastic diseases. Cardioselective beta-blockers should generally be avoided, or used with extreme caution if no other alternatives are available and the benefits outweigh the risks of potentially severe bronchospasm. If patients do receive this combination, they should be closely monitored for increased serum theophylline levels but decreased bronchodilatory effectiveness.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426614, 'Oxybutynin', 'Nadolol', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426615, 'Ozanimod', 'Nadolol', 'Moderate', 'The risk of transient bradycardia and atrioventricular (AV) block may be increased during initiation of ozanimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis. Ozanimod can cause a decrease in heart rate during initiation of therapy.', NULL, 'Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.', NULL, 'Ozanimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. In addition, advice from a cardiologist should be sought if coadministration of ozanimod is considered in patients with significant QT prolongation (QTcF greater than 450 msec in males or 470 msec in females), patients with arrhythmias requiring treatment with Class 1a or Class III antiarrhythmic agents, patients with ischemic heart disease, heart failure, history of cardiac arrest or myocardial infarction, cerebrovascular disease, or uncontrolled hypertension. Use of ozanimod in patients with a history of second-degree Mobitz type II or higher AV block, sick-sinus syndrome, or sinoatrial heart block is considered contraindicated unless the patient has a functioning pacemaker.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426616, 'Pancuronium', 'Nadolol', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426617, 'Pentazocine', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426618, 'Pentoxifylline', 'Nadolol', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426619, 'Phenobarbital', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426620, 'Phenylbutazone', 'Nadolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426621, 'Physostigmine', 'Nadolol', 'Moderate', 'Severe bradycardia and hypotension may develop during concomitant administration of some beta-blockers and anticholinesterase agents. The mechanism is unknown but may involve additive effects.', NULL, 'The patient''s hemodynamic status should be monitored during coadministration.', NULL, 'The patient''s hemodynamic status should be monitored during coadministration. Patients should be advised to notify their physician if they experience syncope, orthostasis, or a slow pulse.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426622, 'Bendroflumethiazide', 'Pimozide', 'Major', 'Pimozide can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of pimozide and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.', NULL, 'Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with pimozide.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426623, 'Bendroflumethiazide', 'Pindolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426624, 'Piroxicam', 'Nadolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426625, 'Prazosin', 'Nadolol', 'Moderate', 'Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.', NULL, 'Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426626, 'Prednisolone', 'Nadolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426627, 'Prednisone', 'Nadolol', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426628, 'Procarbazine', 'Nadolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426629, 'Promazine', 'Nadolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426630, 'Propantheline', 'Nadolol', 'Moderate', 'Anticholinergic agents frequently cause drowsiness and other central nervous system-depressant effects that may be additive with those induced by beta blockers. In addition, these agents may increase heart rate and theoretically may counteract the bradycardic effects of beta blockers. Pharmacokinetically, anticholinergic agents may delay the gastrointestinal absorption of beta blockers and other drugs that are administered orally. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.', NULL, 'Patients should be monitored for potentially excessive CNS adverse effects (e.g., drowsiness, dizziness, lightheadedness, confusion, blurred vision) if anticholinergic agents are used in combination with beta blockers. Patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.', 'Synergism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426631, 'Dextropropoxyphene', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426632, 'Bendroflumethiazide', 'Propranolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426633, 'Bendroflumethiazide', 'Quinapril', 'Moderate', 'Although they are frequently combined in clinical practice, diuretics and angiotensin converting enzyme (ACE) inhibitors may have additive effects. Coadministration makes hypotension and hypovolemia more likely than does either drug alone. Some ACE inhibitors may attenuate the increase in the urinary excretion of sodium caused by some loop diuretics. Some patients on diuretics, especially those on dialysis or a dietary salt restriction, may experience acute hypotension with lightheadedness and dizziness after receiving the first dose of the ACE inhibitor. In addition, ACE inhibitors may cause renal insufficiency or acute renal failure in patients with sodium depletion or renal artery stenosis.', NULL, 'Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration.', NULL, 'Monitoring of blood pressure, diuresis, electrolytes, and renal function is recommended during coadministration. The possibility of first-dose hypotensive effects may be minimized by initiating therapy with small doses of the ACE inhibitor, or either discontinuing the diuretic temporarily or increasing the salt intake approximately one week prior to initiating an ACE inhibitor. Alternatively, the patient may remain under medical supervision for at least two hours after the first dose of the ACE inhibitor, or until blood pressure has stabilized.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426634, 'Quinidine', 'Nadolol', 'Moderate', 'Quinidine and beta-blockers may have additive negative inotropic effects, which can be beneficial when used to treat atrial fibrillation. However, adverse effects have been reported with quinidine and some beta blockers.', NULL, 'Patients should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.', NULL, 'Patients should be monitored for orthostatic hypotension, cardiac arrhythmias, bradycardia, and heart failure, and beta-blocker dosage should be decreased if necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426635, 'Racepinephrine', 'Nadolol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426636, 'Reserpine', 'Nadolol', 'Moderate', 'Sympathetic ganglion-blocking or catecholamine-depleting agents such as guanethidine, reserpine, and monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta-blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons. Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents.', NULL, 'Caution is advised if beta-blockers, including ophthalmic formulations, are prescribed in combination with sympathetic ganglion-blocking or catecholamine-depleting agents. Patients should contact their doctor if they experience dizziness, lightheadedness, syncope, bradycardia, shortness of breath, difficulty breathing, edema, and/or chest pain.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426637, 'Ritodrine', 'Nadolol', 'Major', 'The use of a nonselective beta blocker with ritodrine (a beta-2 agonist) may result in mutually antagonistic effects, negating the effect of one or both drugs.', NULL, 'In general, the use of beta blockers with ritodrine is discouraged.', NULL, 'In general, the use of beta blockers with ritodrine is discouraged. Selective beta blockers (e.g. acebutolol, atenolol, betaxolol, bisoprolol, metoprolol) may be preferable if the use of a beta blocker is unavoidable.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426638, 'Salmeterol', 'Nadolol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426639, 'Saquinavir', 'Nadolol', 'Major', 'Saquinavir in combination with ritonavir has been shown to prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta blockers, digoxin, diltiazem, lacosamide, mefloquine, verapamil) may result in additive effects and increased risk of bradycardia and heart block.', NULL, 'Ritonavir-boosted saquinavir should not be used with other agents that prolong the PR interval.', NULL, 'Ritonavir-boosted saquinavir should not be used with other agents that prolong the PR interval.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426640, 'Secobarbital', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426641, 'Siponimod', 'Nadolol', 'Major', 'The risk of severe bradycardia and atrioventricular (AV) block may be increased during initiation of siponimod treatment in patients receiving other drugs that slow heart rate or AV conduction such as beta-blockers, certain calcium channel blockers (e.g., diltiazem, verapamil), and digitalis.', NULL, 'Siponimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate.', NULL, 'Siponimod has not been adequately studied in patients receiving concomitant therapy with drugs that decrease heart rate. Treatment with siponimod should generally not be initiated in patients who are concurrently treated with heart rate-lowering drugs. Advice from a cardiologist should be sought if coadministration of siponimod and drugs that slow heart rate or AV conduction is considered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426642, 'Bendroflumethiazide', 'Sotalol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426643, 'Succinylcholine', 'Nadolol', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426644, 'Sufentanil', 'Nadolol', 'Moderate', 'In patients receiving chronic beta-blocker therapy, the use of sufentanil may lead to a higher degree of bradycardia and hypotension. One study has shown that induction and maintenance of anesthesia requires lower doses of sufentanil in patients receiving beta-blockers.', NULL, 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', NULL, 'Patients should be carefully observed for clinically significant alterations in hemodynamics.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426645, 'Sulindac', 'Nadolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426646, 'Temazepam', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426647, 'Terazosin', 'Nadolol', 'Moderate', 'Additive hypotensive effects may occur when beta-blockers are used in combination with alpha-blockers. In the presence of beta-blockade, the risk and/or severity of first-dose effects associated with alpha-blockers such as postural hypotension and syncope may be increased. Beta-blockers may also blunt the reflex tachycardia that occurs in response to postural hypotension. Theoretically, the interaction may also occur with beta-blocker ophthalmic preparations, since they may be systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels.', NULL, 'Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations.', NULL, 'Caution is advised during coadministration of these agents, particularly when initiating an alpha-blocker in the presence of a beta-blocker, including ophthalmic formulations. Small initial dosages of the alpha-blocker should be considered and gradually titrated to desired effect, while the systemic beta-blocker dosage may also need to be reduced. Hemodynamic responses should be monitored, especially during the first few weeks of therapy. Taking the alpha-blocker at bedtime may minimize the occurrence of orthostatic effects. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426648, 'Terbutaline', 'Nadolol', 'Major', 'Beta-blockers may antagonize the effects of beta-2 adrenergic bronchodilators and precipitate acute, life-threatening bronchospasm in patients with asthma or other obstructive airway diseases. The mechanism involves increased airway resistance and reduced bronchodilation due to blockade of beta-2 adrenergic receptors. The interaction may also occur with ophthalmically applied beta-blockers, which are systemically absorbed and can produce clinically significant systemic effects even at low or undetectable plasma levels. Due to opposing effects on beta-2 adrenergic receptors, propranolol has been used in the treatment of albuterol overdose. Likewise, beta-2 adrenergic agonists may interfere with the pharmacologic effects of beta-blockers.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided.', NULL, 'Concomitant use of beta-2 adrenergic bronchodilators with beta-blockers, including ophthalmic formulations, should generally be avoided. If coadministration is required, a cardioselective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol) is usually preferred. Nevertheless, caution is advised and respiratory status should be closely monitored, as cardioselectivity is not absolute and larger doses of beta-1 selective agents may pose some of the same risks as nonselective agents. In general, nonselective beta-blockers are considered contraindicated in patients with obstructive airways disease.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426649, 'Thioridazine', 'Nadolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426650, 'Thiothixene', 'Nadolol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426651, 'Tizanidine', 'Bendroflumethiazide', 'Major', 'Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426652, 'Tocainide', 'Nadolol', 'Moderate', 'The concomitant use of tocainide and beta-blockers may have additive effects on cardiac index, left ventricular function, and pulmonary wedge pressure. While significant interactions have not been reported in studies, cases of asystole have been reported in patients with preexisting electrophysiologic abnormalities after tocainide and metoprolol were coadministered. The mechanism is not known, but may be related to an additive effect on the sinus node or conduction system, especially in patients with sick sinus syndrome. Cases of confusion and paranoia have also been reported after coadministration of tocainide and propranolol.', NULL, 'The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome.', NULL, 'The concomitant use of tocainide and beta blockers should probably be avoided in patients with atrioventricular conduction abnormalities or sick sinus syndrome. This combination should be used cautiously in other patients, with careful dose titration and close clinical and electrocardiographic monitoring for efficacy and safety.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426653, 'Tolazamide', 'Nadolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426654, 'Tolbutamide', 'Nadolol', 'Moderate', 'Beta-blockers may inhibit some of the normal physiologic response to hypoglycemia. Symptoms of hypoglycemia such as tremor and tachycardia may be absent, making it more difficult for patients to recognize an oncoming episode. Specifically, inhibition of catecholamine-mediated glycogenolysis and glucose mobilization in association with beta-blockade can potentiate insulin-induced hypoglycemia in diabetics and delay the recovery of normal blood glucose levels. Prolonged and severe hypoglycemia may occur, although these events have rarely been reported. Significant increases in blood pressure and bradycardia can also occur during hypoglycemia in diabetics treated with insulin and beta-blockers due to antagonism of epinephrine''s effect on beta-2 adrenergic receptors, which leads to unopposed alpha-adrenergic effects including vasoconstriction. Other effects reported with various beta-blockers include decreased glucose tolerance and decreased glucose-induced insulin secretion.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients.', NULL, 'In general, cardioselective beta-blockers are considered safer than noncardioselective agents in the treatment of diabetic patients. Patients should be advised of the need for regular blood glucose monitoring and be aware that certain symptoms of hypoglycemia such as tremor and tachycardia may be masked. However, other symptoms such as headache, dizziness, drowsiness, confusion, nausea, hunger, weakness, and perspiration may be unaffected.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426655, 'Tolmetin', 'Nadolol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426656, 'Trazodone', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426657, 'Triamterene', 'Nadolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', NULL, 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426658, 'Triazolam', 'Nadolol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426659, 'Vecuronium', 'Nadolol', 'Moderate', 'Neuromuscular blocking agents and beta-blockers may have additive cardiovascular depressant effects. Limited data suggest that beta-blockers may modestly potentiate the pharmacologic effects of neuromuscular blocking agents. The exact mechanism of interaction is unknown but may involve effects in the postsynaptic membrane, as beta-blockers alone have been reported to exacerbate or unmask myasthenia gravis.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers.', NULL, 'Clinicians should recognize the potential for altered effects of neuromuscular blocking agents in the presence of beta-blockers. Respiratory and cardiovascular status should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426660, 'Ziprasidone', 'Bendroflumethiazide', 'Major', 'Ziprasidone can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of ziprasidone and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.', NULL, 'Caution is advised when ziprasidone must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', NULL, 'Caution is advised when ziprasidone must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with ziprasidone. Patients should be advised to notify their physician if they experience possible signs of an electrolyte imbalance, such as weakness, lethargy, drowsiness, confusion, muscle pains or cramps, dizziness, nausea, vomiting, tachycardia, or an irregular heartbeat.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426661, 'Flumazenil', 'Nalmefene', 'Minor', 'Both nalmefene and flumazenil have been shown to produce seizures in animals. Coadministration has not been shown to increase the risk of seizures in humans, but caution is recommended if nalmefene and flumazenil must be administered together.', NULL, '-', NULL, '-', 'Others', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426662, 'Glimepiride', 'Nalmefene', 'Moderate', 'The hypoglycemic action of glimepiride may be potentiated by highly protein-bound drugs. The mechanism is displacement of glimepiride from protein-binding sites, resulting in higher plasma concentrations of unbound glimepiride available to act on pancreatic beta cells.', NULL, 'Patients should be monitored closely for hypoglycemia during concomitant therapy, particularly following addition of a highly protein-bound drug to a stabilized glimepiride regimen.', NULL, 'Patients should be monitored closely for hypoglycemia during concomitant therapy, particularly following addition of a highly protein-bound drug to a stabilized glimepiride regimen. Patients should be advised to regularly monitor their blood sugar, counseled on how to recognize and treat hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, tremor, hunger, weakness, or palpitations) and to notify their physician if it occurs. Likewise, such patients should be observed for loss of glycemic control when the highly protein-bound drug is withdrawn.', 'Distribution', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426663, 'Nalmefene', 'Levacetylmethadol', 'Moderate', 'The administration of narcotic antagonists or mixed agonists/antagonists may precipitate withdrawal symptoms in patients maintained on levomethadyl acetate.', NULL, 'Caution is recommended if narcotic antagonists are administered and patients should be closely monitored for withdrawal symptoms.', NULL, 'Caution is recommended if narcotic antagonists are administered and patients should be closely monitored for withdrawal symptoms.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426664, 'Naldemedine', 'Nalmefene', 'Moderate', 'Coadministration of naloxegol or naldemedine with other opioid antagonists may result in additive pharmacologic effects and increased risk of opioid withdrawal.', NULL, 'Concomitant use of naloxegol or naldemedine with other opioid antagonists should generally be avoided.', NULL, 'Concomitant use of naloxegol or naldemedine with other opioid antagonists should generally be avoided.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426665, 'Naloxegol', 'Nalmefene', 'Moderate', 'Coadministration of naloxegol or naldemedine with other opioid antagonists may result in additive pharmacologic effects and increased risk of opioid withdrawal.', NULL, 'Concomitant use of naloxegol or naldemedine with other opioid antagonists should generally be avoided.', NULL, 'Concomitant use of naloxegol or naldemedine with other opioid antagonists should generally be avoided.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426666, 'Dezocine', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426667, 'Fenfluramine', 'Naloxone', 'Minor', 'According to one case report, fenfluramine and naloxone given together synergistically released adrenocorticotrophic hormone. The mechanisms involve the central nervous system, pituitary levels, and the hypothalamus. The clinical significance is unknown.', NULL, '-', NULL, '-', 'Synergism', NULL, NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426668, 'Diamorphine', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426669, 'Hydromorphone', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426670, 'Naloxone', 'Levacetylmethadol', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426671, 'Naloxone', 'Levorphanol', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426672, 'Naloxone', 'Meperidine', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426673, 'Nalbuphine', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426674, 'Oliceridine', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426675, 'Opium', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426676, 'Oxymorphone', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426677, 'Pentazocine', 'Naloxone', 'Moderate', 'This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines. Naloxone injection is an antagonist that will reverse the actions of opiates. This reversal can occur when the opiate drug is being used clinically and when it is being abused. Physically dependent patients may experience withdrawal symptoms. Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', NULL, 'Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426678, 'Tapentadol', 'Naloxone', 'Moderate', 'Concomitant use of pure opioid antagonists, such as naloxone and naltrexone may reduce the therapeutic effects and/or precipitate withdrawal symptoms in patients treated with tramadol or tapentadol. The partial analgesic activity of tramadol or tapentadol due to mu-opioid receptor agonist activity can be antagonized by the mu-opioid receptor antagonists naloxone and naltrexone.', NULL, 'Caution and clinical monitoring are recommended when pure opioid antagonists, such as naloxone and naltrexone are used concomitantly with tramadol or tapentadol.', NULL, 'Caution and clinical monitoring are recommended when pure opioid antagonists, such as naloxone and naltrexone are used concomitantly with tramadol or tapentadol. A non-opioid therapeutic alternative or a dosage adjustment for tramadol or tapentadol may be considered if concomitant use of an opioid antagonist is unavoidable. Patients with a suspected tramadol overdose should be closely monitored for seizure activity if an opioid antagonist is used to treat the overdose.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426679, 'Ethionamide', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426680, 'Naltrexone', 'Ketoprofen', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426681, 'Naltrexone', 'Levacetylmethadol', 'Major', 'Naltrexone can antagonize the effects of opioids via competitive inhibition of opioid receptors. Patients receiving naltrexone may not benefit from opioid-containing medications such as cough and cold products, antidiarrheal preparations, and narcotic analgesics. Likewise, patients dependent on opioids may experience withdrawal symptoms when given naltrexone. Following use of naltrexone, patients may have increased sensitivity to opioids.', NULL, 'The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.', NULL, 'The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). Naltrexone should also not be given to patients in acute opioid withdrawal. In an urgent situation when analgesia may be required in a patient who has received full blocking doses of naltrexone, consideration should be given to regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics, or general anesthesia. If opioid analgesia is required, the amount of opioid needed may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged. A rapidly-acting opioid analgesic that minimizes the duration of respiratory depression is preferred. Clinicians should be aware that reversal of full naltrexone blockade by administration of large doses of opiates can cause histamine release. Therefore, patients may experience non-opioid receptor-mediated effects such as facial swelling, itching, generalized erythema, and bronchoconstriction. Irrespective of the drug chosen to reverse naltrexone blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426682, 'Naltrexone', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.', NULL, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426683, 'Naltrexone', 'Meclofenamic acid', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426684, 'Naltrexone', 'Mefenamic acid', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426685, 'Naltrexone', 'Morphine (liposomal)', 'Major', 'Naltrexone can antagonize the effects of opioids via competitive inhibition of opioid receptors. Patients receiving naltrexone may not benefit from opioid-containing medications such as cough and cold products, antidiarrheal preparations, and narcotic analgesics. Likewise, patients dependent on opioids may experience withdrawal symptoms when given naltrexone. Following use of naltrexone, patients may have increased sensitivity to opioids.', NULL, 'The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.', NULL, 'The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). Naltrexone should also not be given to patients in acute opioid withdrawal. In an urgent situation when analgesia may be required in a patient who has received full blocking doses of naltrexone, consideration should be given to regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics, or general anesthesia. If opioid analgesia is required, the amount of opioid needed may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged. A rapidly-acting opioid analgesic that minimizes the duration of respiratory depression is preferred. Clinicians should be aware that reversal of full naltrexone blockade by administration of large doses of opiates can cause histamine release. Therefore, patients may experience non-opioid receptor-mediated effects such as facial swelling, itching, generalized erythema, and bronchoconstriction. Irrespective of the drug chosen to reverse naltrexone blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426686, 'Naproxen', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426687, 'Propylthiouracil', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426688, 'Remifentanil', 'Naltrexone', 'Major', 'Naltrexone can antagonize the effects of opioids via competitive inhibition of opioid receptors. Patients receiving naltrexone may not benefit from opioid-containing medications such as cough and cold products, antidiarrheal preparations, and narcotic analgesics. Likewise, patients dependent on opioids may experience withdrawal symptoms when given naltrexone. Following use of naltrexone, patients may have increased sensitivity to opioids.', NULL, 'The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.', NULL, 'The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine). Naltrexone should also not be given to patients in acute opioid withdrawal. In an urgent situation when analgesia may be required in a patient who has received full blocking doses of naltrexone, consideration should be given to regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics, or general anesthesia. If opioid analgesia is required, the amount of opioid needed may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged. A rapidly-acting opioid analgesic that minimizes the duration of respiratory depression is preferred. Clinicians should be aware that reversal of full naltrexone blockade by administration of large doses of opiates can cause histamine release. Therefore, patients may experience non-opioid receptor-mediated effects such as facial swelling, itching, generalized erythema, and bronchoconstriction. Irrespective of the drug chosen to reverse naltrexone blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.', 'Antagonism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426689, 'Sulfamethizole', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426690, 'Sulfisoxazole', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426691, 'Tolmetin', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426692, 'Esomeprazole', 'Naproxen', 'Moderate', 'Theoretically, proton pump inhibitors may decrease the gastrointestinal absorption of enteric-coated naproxen, which requires an acidic environment for dissolution. The proposed mechanism is an increase in gastric pH (i.e. decreased gastric acidity) induced by proton pump inhibitors. In patients treated with proton pump inhibitors, the possibility of a reduced or subtherapeutic response to enteric-coated naproxen should be considered.', NULL, 'Concomitant use of these drugs is generally not recommended.', NULL, 'Concomitant use of these drugs is generally not recommended.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426693, 'Acetohexamide', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426694, 'Aminolevulinic acid', 'Naproxen', 'Major', 'Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.', NULL, 'Photosensitizing agents (e.', NULL, 'Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John''s wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426695, 'Amphotericin B (cholesteryl sulfate)', 'Esomeprazole', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426696, 'Anisindione', 'Naproxen', 'Major', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the hypoprothrombinemic effect and bleeding risk associated with oral anticoagulants.', NULL, 'NSAIDs should be administered with oral anticoagulants only if benefit outweighs risk.', NULL, 'NSAIDs should be administered with oral anticoagulants only if benefit outweighs risk. The INR should be checked frequently and oral anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of NSAIDs in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools. Salicylates (except aspirin) appear to have less effect on coagulation and may be preferable in patients treated with oral anticoagulants.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426697, 'Anistreplase', 'Naproxen', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426698, 'Naproxen', 'Ardeparin', 'Major', 'In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426699, 'Naproxen', 'Argatroban', 'Moderate', 'Theoretically, the coadministration of nonsteroidal anti-inflammatory drugs (NSAIDs) and thrombin inhibitors may potentiate the risk of bleeding. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals.', NULL, 'Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving thrombin inhibitors.', NULL, 'Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving thrombin inhibitors. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426700, 'Esomeprazole', 'Bacampicillin', 'Moderate', 'Coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents with acid neutralizing or reducing effects may decrease the oral bioavailability and plasma concentrations of ampicillin from bacampicillin. The exact mechanism of interaction is unknown but may be related to degradation of the prodrug when gastric pH is increased.', NULL, 'The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH.', NULL, 'The possibility of a reduced or subtherapeutic response to bacampicillin should be considered during coadministration with antacids, H2-receptor antagonists, proton pump inhibitors, or other agents that can increase gastric pH. Preferably, these agents should be avoided during therapy with bacampicillin, or an alternative antibiotic be prescribed if these medications cannot be discontinued. Patients treated with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) may minimize the effects of the interaction with bacampicillin by separating the times of administration by at least 2 hours.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426701, 'Bendroflumethiazide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426702, 'Benzthiazide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426703, 'Bepridil', 'Naproxen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', NULL, 'Monitoring for altered blood pressure control is recommended.', NULL, 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426704, 'Bromfenac', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426705, 'Iron', 'Esomeprazole', 'Moderate', 'The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent on an acidic environment.', NULL, 'Patients with iron deficiency may not respond adequately to oral iron replacement therapy during coadministration of proton pump inhibitors.', NULL, 'Patients with iron deficiency may not respond adequately to oral iron replacement therapy during coadministration of proton pump inhibitors. If an interaction is suspected after ruling out other causes, it may be appropriate to discontinue the proton pump inhibitor or consider administering iron parenterally.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426706, 'Carteolol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426707, 'Cinoxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426708, 'Danaparoid', 'Naproxen', 'Major', 'In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426709, 'Desmopressin', 'Naproxen', 'Moderate', 'The antidiuretic response to vasopressin or desmopressin may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, tricyclic/tetracyclic antidepressants, carbamazepine, chlorpropamide, chlorpromazine, clofibrate, eslicarbazepine, fludrocortisone, haloperidol, lamotrigine, oxcarbazepine, urea, and some antineoplastic agents (e.g., vinca alkaloids, cisplatin, cyclophosphamide). These drugs can occasionally cause fluid retention, in some cases secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Coadministration with vasopressin or desmopressin may, therefore, increase the risk of water intoxication and/or hyponatremia. Seizure and coma in association with severe hyponatremia have been reported during concomitant use of desmopressin and imipramine or ibuprofen.', NULL, 'Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH.', NULL, 'Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH. Some authorities recommend adjusting vasopressin dosage as needed. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426710, 'Dexfenfluramine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426711, 'Dicoumarol', 'Naproxen', 'Major', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the hypoprothrombinemic effect and bleeding risk associated with oral anticoagulants.', NULL, 'NSAIDs should be administered with oral anticoagulants only if benefit outweighs risk.', NULL, 'NSAIDs should be administered with oral anticoagulants only if benefit outweighs risk. The INR should be checked frequently and oral anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of NSAIDs in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools. Salicylates (except aspirin) appear to have less effect on coagulation and may be preferable in patients treated with oral anticoagulants.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426712, 'Diflunisal', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426713, 'Drotrecogin alfa', 'Naproxen', 'Major', 'Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT).', NULL, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia.', NULL, 'The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who are currently receiving, or have recently received, agents that could interfere with coagulation such as salicylates, NSAIDs, low molecular weight heparins, thrombolytics, thrombin inhibitors, platelet inhibitors, or agents that commonly cause thrombocytopenia. Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426714, 'Echinacea', 'Naproxen', 'Moderate', 'Coadministration with echinacea may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to echinacea-mediated inhibition of CYP450 1A2.', NULL, 'Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if echinacea is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever echinacea is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426715, 'Enoxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426716, 'Enoxaparin', 'Naproxen', 'Major', 'In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426717, 'Epoprostenol', 'Naproxen', 'Moderate', 'Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.', NULL, 'Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426718, 'Eprosartan', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426719, 'Eptifibatide', 'Naproxen', 'Moderate', 'The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive inhibitory effects on platelet function. Arterial puncture sites may be most problematic.', NULL, 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.', NULL, 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426720, 'Esomeprazole', 'Erlotinib', 'Major', 'Concurrent administration of agents that increase gastric pH such as proton pump inhibitors may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption. Moreover, since proton pump inhibitors affect pH of the upper gastrointestinal tract for an extended period, separation of doses may not eliminate the interaction.', NULL, 'The concomitant use of erlotinib with proton pump inhibitors should generally be avoided.', NULL, 'The concomitant use of erlotinib with proton pump inhibitors should generally be avoided. If acid-suppression therapy is required during erlotinib treatment, an H2-receptor antagonist such as ranitidine may be considered. Available pharmacokinetic data suggest that erlotinib should be administered once a day, at least 2 hours before or 10 hours after dosing of the H2-receptor antagonist. Additionally, the lowest effective dosage of the H2-receptor antagonist should be prescribed.', 'Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426721, 'Esmolol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426722, 'Etacrynic acid', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426723, 'Etidronic acid', 'Naproxen', 'Moderate', 'Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.', NULL, 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426724, 'Etodolac', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426725, 'Everolimus', 'Naproxen', 'Major', 'Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426726, 'Felodipine', 'Naproxen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', NULL, 'Monitoring for altered blood pressure control is recommended.', NULL, 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426727, 'Fenfluramine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426728, 'Fenoprofen', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426729, 'Ferrous fumarate', 'Esomeprazole', 'Moderate', 'The profound hypochlorhydria induced by proton pump inhibitors (PPIs) may impair the gastrointestinal absorption of nonheme iron, a process that is dependent on an acidic environment.', NULL, 'Patients with iron deficiency may not respond adequately to oral iron replacement therapy during coadministration of proton pump inhibitors.', NULL, 'Patients with iron deficiency may not respond adequately to oral iron replacement therapy during coadministration of proton pump inhibitors. If an interaction is suspected after ruling out other causes, it may be appropriate to discontinue the proton pump inhibitor or consider administering iron parenterally.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426730, 'Fluconazole', 'Esomeprazole', 'Moderate', 'Coadministration with fluconazole may significantly increase the plasma concentrations of omeprazole and other proton pump inhibitors (PPIs). The proposed mechanism is fluconazole inhibition of PPI metabolism via CYP450 2C19 and 3A4.', NULL, 'According to the manufacturers, dosage adjustment of omeprazole is not normally required when used with dual inhibitors of CYP450 2C19 and 3A4 such as fluconazole.', NULL, 'According to the manufacturers, dosage adjustment of omeprazole is not normally required when used with dual inhibitors of CYP450 2C19 and 3A4 such as fluconazole. However, it may be necessary in patients receiving higher dosages, such as those with Zollinger-Ellison syndrome. Patients should be monitored for potentially increased adverse effects of PPIs during coadministration with fluconazole. The same precaution may be applicable to other PPIs.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426731, 'Flucytosine', 'Naproxen', 'Moderate', 'Drugs that impair glomerular filtration may prolong the half-life of flucytosine and lead to accumulation.', NULL, 'Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.', NULL, 'Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).', 'Excretion', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426732, 'Fludrocortisone', 'Naproxen', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426733, 'Fluoxetine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426734, 'Flurbiprofen', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426735, 'Fluvoxamine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426736, 'Fondaparinux', 'Naproxen', 'Major', 'In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with the use of fondaparinux. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals.', NULL, 'Products containing NSAIDs, especially if given chronically or in high dosages, should preferably be discontinued prior to initiation of fondaparinux therapy.', NULL, 'Products containing NSAIDs, especially if given chronically or in high dosages, should preferably be discontinued prior to initiation of fondaparinux therapy. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426737, 'Foscarnet', 'Esomeprazole', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426738, 'Fosinopril', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426739, 'Furosemide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426740, 'Gatifloxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426741, 'Gentamicin', 'Naproxen', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426742, 'Glimepiride', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426743, 'Glipizide', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426744, 'Glyburide', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426745, 'Grepafloxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426746, 'Heparin', 'Naproxen', 'Moderate', 'Theoretically, the coadministration of nonsteroidal anti-inflammatory drugs (NSAIDs) and heparin or low molecular weight heparin (LMWH) may potentiate the risk of bleeding. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. In addition, NSAIDs are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.', NULL, 'Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving heparin or LMWH.', NULL, 'Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving heparin or LMWH. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426747, 'Hydralazine', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426748, 'Hydroflumethiazide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426749, 'Ibritumomab tiuxetan', 'Naproxen', 'Major', 'Coadministration of ibritumomab and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', NULL, 'Caution is advised if ibritumomab is used in combination with drugs that interfere with platelet function or coagulation.', NULL, 'Caution is advised if ibritumomab is used in combination with drugs that interfere with platelet function or coagulation. Close clinical and laboratory observation for bleeding complications is recommended during and after ibritumomab therapy.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426750, 'Ibrutinib', 'Naproxen', 'Major', 'Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426751, 'Idelalisib', 'Naproxen', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with idelalisib should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426752, 'Imipramine', 'Esomeprazole', 'Moderate', 'Coadministration with esomeprazole may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is decreased clearance due to esomeprazole-mediated inhibition of CYP450 2C19.', NULL, 'Although a clinically significant interaction is unlikely, caution is advised if esomeprazole is used concomitantly with drugs that are substrates of CYP450 2C19.', NULL, 'Although a clinically significant interaction is unlikely, caution is advised if esomeprazole is used concomitantly with drugs that are substrates of CYP450 2C19. Clinical and laboratory monitoring may be appropriate whenever esomeprazole is added to or withdrawn from therapy with these drugs. Dosage adjustments may be considered if an interaction is suspected. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426753, 'Human immunoglobulin G (intravenous and subcutaneous)', 'Naproxen', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426754, 'Indapamide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426755, 'Indinavir', 'Esomeprazole', 'Moderate', 'Proton pump inhibitors may decrease the gastrointestinal absorption of indinavir. The proposed mechanism is a pH-dependent reduction in drug dissolution or absorption. The interaction has been reported specifically with omeprazole but may be expected with other proton pump inhibitors based on their common pharmacologic action.', NULL, 'Caution is advised during the chronic use of these drugs with indinavir due to the risk of treatment failure and emergence of drug resistance associated with subtherapeutic levels of indinavir.', NULL, 'Caution is advised during the chronic use of these drugs with indinavir due to the risk of treatment failure and emergence of drug resistance associated with subtherapeutic levels of indinavir. Patients should be monitored for altered antiviral effectiveness.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426756, 'Indomethacin', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426757, 'Inotersen', 'Naproxen', 'Major', 'Coadministration of inotersen and drugs that interfere with platelet function such as nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of serious, potentially life-threatening bleeding complications, including spontaneous intracranial and intrapulmonary hemorrhage. Inotersen causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia. Coadministration of inotersen with other potentially nephrotoxic agents such as NSAIDs may increase the risk of renal impairment due to additive adverse effects on the kidney. Inotersen can cause glomerulonephritis that may result in dialysis-dependent renal failure.', NULL, 'Caution is advised when inotersen is prescribed with NSAIDs.', NULL, 'Caution is advised when inotersen is prescribed with NSAIDs. A platelet count should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling. Inotersen should not be administered in patients with a platelet count below 100 x 10^9/L or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines. Patients or their caregivers should be apprised of the signs and symptoms of thrombocytopenia and to seek medical attention if they occur, including any unusual or prolonged bleeding (e.g., petechiae, easy bruising, hematoma, subconjunctival bleeding, gingival bleeding, epistaxis, hemoptysis, irregular or heavier than normal menstrual bleeding, hematemesis, hematuria, hematochezia, melena), neck stiffness, or atypical severe headache. Caution is advised when inotersen is prescribed with high dosages and/or chronic use of NSAIDs. Serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and a urinalysis should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling. Inotersen should generally not be initiated in patients with a UPCR of 1000 mg/g or higher, or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines. Patients or their caregivers should be apprised of the signs and symptoms of glomerulonephritis and to seek medical attention if they occur, including edema, shortness of breath, coughing, hematuria, and decreased urination.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426758, 'Interferon beta-1a', 'Naproxen', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426759, 'Interferon beta-1b', 'Naproxen', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426760, 'Tositumomab (I-131)', 'Naproxen', 'Major', 'Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia.', NULL, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.', NULL, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426761, 'Iodipamide', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426762, 'Iodixanol', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426763, 'Iohexol', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426764, 'Iopamidol', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426765, 'Iopromide', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426766, 'Ioversol', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426767, 'Ioxilan', 'Naproxen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426768, 'Irbesartan', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426769, 'Itraconazole', 'Esomeprazole', 'Moderate', 'Proton pump inhibitors may decrease the gastrointestinal absorption of the azole antifungal agents, itraconazole and ketoconazole, both of which require an acidic environment for dissolution. By increasing gastric pH and reducing the acidity, proton pump inhibitors can decrease bioavailability of the azoles by 75% to 80%.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose. Administration with an acidic beverage such as Coca-Cola(R) or Pepsi(R) may also help. However, clinicians should still consider the possibility of a reduced or subtherapeutic antifungal effect. It may be appropriate to switch to an agent like fluconazole or terbinafine whose absorption is not affected by stomach pH.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426770, 'Naproxen', 'Kanamycin', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426771, 'Esomeprazole', 'Ketoconazole', 'Moderate', 'Proton pump inhibitors may decrease the gastrointestinal absorption of the azole antifungal agents, itraconazole and ketoconazole, both of which require an acidic environment for dissolution. By increasing gastric pH and reducing the acidity, proton pump inhibitors can decrease bioavailability of the azoles by 75% to 80%.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose. Administration with an acidic beverage such as Coca-Cola(R) or Pepsi(R) may also help. However, clinicians should still consider the possibility of a reduced or subtherapeutic antifungal effect. It may be appropriate to switch to an agent like fluconazole or terbinafine whose absorption is not affected by stomach pH.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426772, 'Naproxen', 'Ketoprofen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426773, 'Naproxen', 'Labetalol', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426774, 'Naproxen', 'Lansoprazole', 'Moderate', 'Theoretically, proton pump inhibitors may decrease the gastrointestinal absorption of enteric-coated naproxen, which requires an acidic environment for dissolution. The proposed mechanism is an increase in gastric pH (i.e. decreased gastric acidity) induced by proton pump inhibitors. In patients treated with proton pump inhibitors, the possibility of a reduced or subtherapeutic response to enteric-coated naproxen should be considered.', NULL, 'Concomitant use of these drugs is generally not recommended.', NULL, 'Concomitant use of these drugs is generally not recommended.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426775, 'Naproxen', 'Leflunomide', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.', NULL, 'Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity.', NULL, 'Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426776, 'Naproxen', 'Lepirudin', 'Moderate', 'Theoretically, the coadministration of nonsteroidal anti-inflammatory drugs (NSAIDs) and thrombin inhibitors may potentiate the risk of bleeding. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals.', NULL, 'Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving thrombin inhibitors.', NULL, 'Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving thrombin inhibitors. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426777, 'Naproxen', 'Levofloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426778, 'Naproxen', 'Lisinopril', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426779, 'Naproxen', 'Lithium carbonate', 'Major', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase serum lithium levels and induce toxicity in some patients. The exact mechanism of interaction is unknown, but is thought to involve inhibition of renal prostaglandin synthesis by NSAIDs, resulting in decreased renal blood flow and lithium excretion. There have been numerous published reports of lithium toxicity, including severe cases, following the introduction of various NSAIDs including diclofenac, ibuprofen, indomethacin, ketorolac, mefenamic acid, piroxicam, and COX-2 inhibitors.', NULL, 'Given the narrow therapeutic index of lithium, caution is advised during coadministration with NSAIDs, particularly in the elderly or patients with other risk factors (e.', NULL, 'Given the narrow therapeutic index of lithium, caution is advised during coadministration with NSAIDs, particularly in the elderly or patients with other risk factors (e.g., sodium restriction; renal impairment; congestive heart failure; dehydration; concomitant use of diuretics, ACE inhibitors, or angiotensin II receptor antagonists). Patients should have serum lithium levels checked every 4 to 5 days after starting an NSAID until the extent of any potential interaction can be evaluated. A reduction in lithium dosage may be needed in some cases. Renal function should also be monitored regularly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of lithium toxicity such as drowsiness, dizziness, confusion, muscle weakness, vomiting, diarrhea, polydipsia, polyuria, tinnitus, tremor, ataxia, and blurred vision.', 'Excretion', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426780, 'Naproxen', 'Lomefloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426781, 'Naproxen', 'Lomitapide', 'Major', 'Coadministration of lomitapide with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Lomitapide can cause elevations in serum transaminases and hepatic steatosis. Clinical data suggest that hepatic fat accumulation is reversible after stopping treatment with lomitapide, although the long-term consequences are unknown.', NULL, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if lomitapide is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients treated with lomitapide should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking lomitapide not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426782, 'Naproxen', 'Losartan', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426783, 'Esomeprazole', 'Lovastatin', 'Moderate', 'A case report suggests that coadministration with esomeprazole may increase the plasma concentrations of atorvastatin and the associated risk of myopathy. The proposed mechanism is competitive inhibition of intestinal P-glycoprotein, resulting in decreased drug secretion into the intestinal lumen and increased drug bioavailability. Another, perhaps minor mechanism is competitive inhibition of CYP450 3A4 metabolism.', NULL, 'Because of the increased risk of musculoskeletal toxicity associated with high levels of HMG-CoA reductase inhibitory activity in plasma, patients treated with atorvastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin) should be monitored more closely during concomitant use of proton pump inhibitors.', NULL, 'Because of the increased risk of musculoskeletal toxicity associated with high levels of HMG-CoA reductase inhibitory activity in plasma, patients treated with atorvastatin, lovastatin, simvastatin, and red yeast rice (which contains lovastatin) should be monitored more closely during concomitant use of proton pump inhibitors. All patients treated with HMG-CoA reductase inhibitors should be advised to promptly report to their physician any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated or if myopathy is suspected or diagnosed.', 'Metabolism, Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426784, 'Naproxen', 'Meclofenamic acid', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426785, 'Naproxen', 'Mefenamic acid', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426786, 'Naproxen', 'Meloxicam', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426787, 'Naproxen', 'Methotrexate', 'Major', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.', NULL, 'NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma.', NULL, 'NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.', 'Excretion', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426788, 'Naproxen', 'Methoxsalen', 'Moderate', 'Concomitant use of methoxsalen with other known photosensitizing agents may increase the risk of photosensitivity reactions. These agents include anthralin, coal tar or coal tar derivatives, griseofulvin, hypericin extracts (e.g., St John''s Wort), fluoroquinolones, phenothiazines, retinoids, halogenated salicylanilides (bacteriostatic soaps), sulfonamides, sulfonylureas, tetracyclines, thiazides, and certain organic staining dyes such as methylene blue, toluidine blue, rose bengal, and methyl orange.', NULL, 'Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided.', NULL, 'Caution is advised and pharmacologic response to methoxsalen therapy should be carefully monitored if concomitant use of other photosensitizing agents cannot be avoided. Patients should be advised to avoid sun exposure, even through window glass or cloud cover, for at least 8 hours after methoxsalen ingestion and during the 24 hours following photochemotherapy or photopheresis treatment.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426789, 'Naproxen', 'Methoxyflurane', 'Moderate', 'Coadministration of methoxyflurane with other nephrotoxic agents may increase the risk of renal impairment. The precise mechanism has not been delineated.', NULL, 'Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided.', NULL, 'Concomitant use of methoxyflurane with other potentially nephrotoxic agents should generally be avoided. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426790, 'Naproxen', 'Methylprednisolone', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426791, 'Naproxen', 'Metolazone', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426792, 'Naproxen', 'Mifepristone', 'Moderate', 'Coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of CYP450 2C8 and/or 2C9. The mechanism is decreased clearance due to inhibition of CYP450 2C8/2C9 activity by mifepristone.', NULL, 'Caution is advised if mifepristone must be used concomitantly with medications that are substrates of CYP450 2C8 and/or 2C9, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if mifepristone must be used concomitantly with medications that are substrates of CYP450 2C8 and/or 2C9, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy. The lowest dosage of sensitive substrates (e.g., repaglinide, warfarin) should be used whenever possible. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426793, 'Naproxen', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426794, 'Naproxen', 'Moexipril', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426795, 'Naproxen', 'Moxifloxacin', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426796, 'Esomeprazole', 'Mycophenolate mofetil', 'Moderate', 'Coadministration with proton pump inhibitors may reduce the bioavailability of mycophenolic acid (MPA) from the administration of mycophenolate mofetil. The exact mechanism of interaction has not been established, but may involve a decrease in MPA solubility at higher gastric pH levels.', NULL, 'Because clinical relevance of this interaction has not been established, proton pump inhibitors should be used with caution in transplant patients receiving mycophenolate mofetil.', NULL, 'Because clinical relevance of this interaction has not been established, proton pump inhibitors should be used with caution in transplant patients receiving mycophenolate mofetil.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426797, 'Naproxen', 'Nabumetone', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426798, 'Naproxen', 'Nalidixic acid', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426799, 'Naproxen', 'Nateglinide', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426800, 'Esomeprazole', 'Nelfinavir', 'Major', 'Concurrent use of proton pump inhibitors may decrease the oral bioavailability of nelfinavir and reduce its concentrations in plasma. Nelfinavir solubility may decrease with increasing pH, thus inhibition of gastric acid secretion may interfere with dissolution of the drug.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, use of proton pump inhibitors is not recommended in patients treated with nelfinavir.', NULL, 'Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiretroviral drug levels, use of proton pump inhibitors is not recommended in patients treated with nelfinavir.', 'Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426801, 'Esomeprazole', 'Neomycin', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426802, 'Esomeprazole', 'Neratinib', 'Major', 'Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of neratinib. The solubility of neratinib is pH-dependent and increases as neratinib becomes protonated at acidic pH, thus an increase in pH may interfere with its absorption.', NULL, 'Concomitant use of neratinib with proton pump inhibitors and H2-receptor antagonists should generally be avoided.', NULL, 'Concomitant use of neratinib with proton pump inhibitors and H2-receptor antagonists should generally be avoided. In addition, short-acting antacids could be considered if acid-suppression therapy is required, with neratinib dosing separated by at least three hours after antacid administration. If coadministered with a gastric acid reducing agent, increasing the dose of neratinib is unlikely to compensate for the loss of bioavailability.', 'Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426803, 'Netilmicin', 'Naproxen', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426804, 'Nicardipine', 'Naproxen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', NULL, 'Monitoring for altered blood pressure control is recommended.', NULL, 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426805, 'Nimodipine', 'Naproxen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', NULL, 'Monitoring for altered blood pressure control is recommended.', NULL, 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426806, 'Nisoldipine', 'Naproxen', 'Moderate', 'Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.', NULL, 'Monitoring for altered blood pressure control is recommended.', NULL, 'Monitoring for altered blood pressure control is recommended.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426807, 'Nizatidine', 'Naproxen', 'Moderate', 'The concomitant administration of H2 blockers may increase the dissolution rate of enteric-coated naproxen, causing the drug to be released in the stomach instead of the small intestine.', NULL, 'H2 antagonists should be avoided in patients taking enteric-coated formulations of naproxen.', NULL, 'H2 antagonists should be avoided in patients taking enteric-coated formulations of naproxen.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426808, 'Norfloxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426809, 'Ofloxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426810, 'Olsalazine', 'Naproxen', 'Moderate', 'Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure.', NULL, 'Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426811, 'Omacetaxine mepesuccinate', 'Naproxen', 'Major', 'Coadministration of omacetaxine and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with omacetaxine is associated with a high frequency of thrombocytopenia.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient''s platelet count is less than 50,000 per microliter.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be avoided if the patient''s platelet count is less than 50,000 per microliter. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The CBC and platelet count should be monitored according to the manufacturer''s recommendations.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426812, 'Omeprazole', 'Naproxen', 'Moderate', 'Theoretically, proton pump inhibitors may decrease the gastrointestinal absorption of enteric-coated naproxen, which requires an acidic environment for dissolution. The proposed mechanism is an increase in gastric pH (i.e. decreased gastric acidity) induced by proton pump inhibitors. In patients treated with proton pump inhibitors, the possibility of a reduced or subtherapeutic response to enteric-coated naproxen should be considered.', NULL, 'Concomitant use of these drugs is generally not recommended.', NULL, 'Concomitant use of these drugs is generally not recommended.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426813, 'Esomeprazole', 'Oxcarbazepine', 'Moderate', 'Coadministration with oxcarbazepine may increase the plasma concentrations of drugs that are substrates of the CYP450 2C19 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 2C19 activity by oxcarbazepine and its active metabolite 10-monohydroxy derivative, or MHD. In vivo, the plasma levels of phenytoin, a CYP450 2C19 substrate, increased by up to 40% when oxcarbazepine was given at dosages above 1200 mg/day.', NULL, 'Caution is advised if higher dosages of oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 2C19, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if higher dosages of oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 2C19, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426814, 'Pamidronic acid', 'Naproxen', 'Moderate', 'Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.', NULL, 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426815, 'Panobinostat', 'Naproxen', 'Major', 'Coadministration of panobinostat and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with panobinostat has been associated with severe thrombocytopenia and hemorrhage (including gastrointestinal and pulmonary hemorrhage) with fatal outcomes. The risk may be increased in patients with coagulation disorders or those on chronic anticoagulation therapy.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with panobinostat. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood cell count should be performed prior to and at least weekly during treatment according to treatment protocols, including monitoring for thrombocytopenia. Dose modifications may be required based on individual patient tolerability. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426816, 'Pantoprazole', 'Naproxen', 'Moderate', 'Theoretically, proton pump inhibitors may decrease the gastrointestinal absorption of enteric-coated naproxen, which requires an acidic environment for dissolution. The proposed mechanism is an increase in gastric pH (i.e. decreased gastric acidity) induced by proton pump inhibitors. In patients treated with proton pump inhibitors, the possibility of a reduced or subtherapeutic response to enteric-coated naproxen should be considered.', NULL, 'Concomitant use of these drugs is generally not recommended.', NULL, 'Concomitant use of these drugs is generally not recommended.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426817, 'Esomeprazole', 'Paromomycin', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', NULL, 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426818, 'Paroxetine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426819, 'Esomeprazole', 'Pazopanib', 'Major', 'Coadministration with proton pump inhibitors or H2-receptor antagonists may significantly decrease the oral bioavailability of pazopanib and reduce its concentrations in plasma. The solubility of pazopanib is pH-dependent, thus an increase in pH may interfere with its absorption.', NULL, 'Concomitant use of pazopanib with proton pump inhibitors and H2-receptor antagonists should generally be avoided.', NULL, 'Concomitant use of pazopanib with proton pump inhibitors and H2-receptor antagonists should generally be avoided. If acid-suppression therapy is required, short-acting antacids should be considered, with dosing separated by several hours from pazopanib dosing. Similarly, when coadministration with an H2-receptor antagonist is required, it has been recommended that pazopanib be taken without food at least 2 hours before or 10 hours after a dose of the H2-receptor antagonist.', 'Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426820, 'Pegaspargase', 'Naproxen', 'Moderate', 'Asparaginase therapy may lead to imbalances in coagulation factors predisposing the patient to bleeding or thrombosis. Theoretically, concurrent use of anticoagulants and asparaginase may increase the risk of bleeding. Hemorrhages grade 3 and above and CNS hemorrhages have been observed with asparaginase treatment.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs.', NULL, 'Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs. Patients should be advised to promptly report any signs and symptoms of bleeding.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426821, 'Penbutolol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426822, 'Pentoxifylline', 'Naproxen', 'Moderate', 'The use of pentoxifylline has been associated with bleeding and/or prolongation in prothrombin time. Theoretically, the risk of bleeding may be increased by concomitant treatment with anticoagulants or other agents that affect hemostasis such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, thrombin inhibitors, thrombolytic agents, and dextran. There have been postmarketing reports of increased anticoagulant activity in patients receiving vitamin K antagonists in combination with pentoxifylline.', NULL, 'Caution is advised if pentoxifylline is administered with anticoagulants or other agents that affect hemostasis.', NULL, 'Caution is advised if pentoxifylline is administered with anticoagulants or other agents that affect hemostasis. Patients on vitamin K antagonists such as warfarin should have more frequent monitoring of INR following initiation or dosage change of pentoxifylline, while patients receiving other agents that affect hemostasis should have periodic examinations for bleeding including hematocrit and/or hemoglobin.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426823, 'Perindopril', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426824, 'Pexidartinib', 'Naproxen', 'Major', 'Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.', NULL, 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided.', NULL, 'The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426825, 'Phenylbutazone', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426826, 'Esomeprazole', 'Phenytoin', 'Moderate', 'Coadministration with esomeprazole may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 2C19. The proposed mechanism is decreased clearance due to esomeprazole-mediated inhibition of CYP450 2C19.', NULL, 'Although a clinically significant interaction is unlikely, caution is advised if esomeprazole is used concomitantly with drugs that are substrates of CYP450 2C19.', NULL, 'Although a clinically significant interaction is unlikely, caution is advised if esomeprazole is used concomitantly with drugs that are substrates of CYP450 2C19. Clinical and laboratory monitoring may be appropriate whenever esomeprazole is added to or withdrawn from therapy with these drugs. Dosage adjustments may be considered if an interaction is suspected. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426827, 'Pindolol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426828, 'Piroxicam', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426829, 'Polythiazide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426830, 'Ponatinib', 'Naproxen', 'Major', 'Coadministration of ponatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with ponatinib is associated with severe, sometimes fatal hemorrhage including cerebral and gastrointestinal hemorrhage.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ponatinib.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ponatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426831, 'Porfimer sodium', 'Naproxen', 'Moderate', 'Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426832, 'Naproxen', 'Monopotassium phosphate', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426833, 'Aminobenzoic acid', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426834, 'Potassium chloride', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426835, 'Potassium gluconate', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426836, 'Potassium Iodide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426837, 'Potassium perchlorate', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) with potassium salts may increase the risk of hyperkalemia. NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.', NULL, 'Closely monitor potassium levels in patients receiving both potassium salts and NSAID therapy, especially those with renal impairment, diabetes, older age, severe or worsening heart failure, dehydration, or concomitant therapy with other agents that increase serum potassium (e.g., beta-blockers, cyclosporine, heparin, tacrolimus, and trimethoprim). Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426838, 'Prasugrel', 'Naproxen', 'Major', 'Concomitant use of prasugrel with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, nonsteroidal anti-inflammatory agents (chronic), or agents that commonly cause thrombocytopenia may increase the risk of bleeding. Prasugrel may be used with aspirin, heparin, or glycoprotein IIb/IIIa inhibitors.', NULL, 'Caution is advised if prasugrel is used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if prasugrel is used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426839, 'Prazosin', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the antihypertensive effect of prazosin. The proposed mechanism is NSAID-induced inhibition of prostaglandin synthesis. Data are available for indomethacin. A similar interaction is expected with other NSAIDs.', NULL, 'The patient''s blood pressure should be monitored during coadministration, and the dosage adjusted as necessary.', NULL, 'The patient''s blood pressure should be monitored during coadministration, and the dosage adjusted as necessary.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426840, 'Prednisolone', 'Naproxen', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426841, 'Prednisone', 'Naproxen', 'Moderate', 'The combined use of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.', NULL, 'Caution is advised if corticosteroids and NSAIDs are used together, especially in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be considered.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426842, 'Propranolol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426843, 'Quinapril', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426844, 'Ramipril', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426845, 'Ramucirumab', 'Naproxen', 'Major', 'Theoretical concerns exist that nonsteroid anti-inflammatory drugs (NSAIDs) and salicylates may potentiate the risk of bleeding and gastrointestinal perforation associated with ramucirumab therapy. Ramucirumab can cause bleeding, including severe and sometimes fatal hemorrhagic complications.', NULL, 'Caution is advised if ramucirumab must be used with chronic NSAID or salicylate therapy.', NULL, 'Caution is advised if ramucirumab must be used with chronic NSAID or salicylate therapy. Close clinical and laboratory observation for bleeding complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Ramucirumab should be permanently discontinued in patients who experience severe bleeding or gastrointestinal perforation.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426846, 'Ranitidine (bismuth citrate)', 'Naproxen', 'Moderate', 'The concomitant administration of H2 blockers may increase the dissolution rate of enteric-coated naproxen, causing the drug to be released in the stomach instead of the small intestine.', NULL, 'H2 antagonists should be avoided in patients taking enteric-coated formulations of naproxen.', NULL, 'H2 antagonists should be avoided in patients taking enteric-coated formulations of naproxen.', 'Absorption', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426847, 'Regorafenib', 'Naproxen', 'Major', 'Coadministration of regorafenib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with regorafenib is associated with a high frequency of hemorrhage and thrombocytopenia. Coadministration of regorafenib with strong UGT1A9 inhibitors such as mefenamic acid or diflunisal may theoretically increase systemic exposure to regorafenib.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib.', NULL, 'Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with regorafenib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426848, 'Repaglinide', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426849, 'Reteplase', 'Naproxen', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426850, 'Human Rho(D) immune globulin', 'Naproxen', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', NULL, 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426851, 'Rifapentine', 'Naproxen', 'Moderate', 'Coadministration with rifapentine may decrease the plasma concentrations of drugs that are substrates of the CYP450 2C8, 2C9, and/or 3A4 isoenzymes. The mechanism is accelerated clearance due to induction of these isoenzymes by rifapentine. Enzyme activities may be induced within 4 days of the first dose and return to normal 14 days after discontinuation of rifapentine.', NULL, 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine.', NULL, 'The possibility of a diminished therapeutic response to drugs that are known substrates of CYP450 2C8, 2C9, and/or 3A4 should be considered during coadministration with rifapentine. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever rifapentine is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426852, 'Rivaroxaban', 'Naproxen', 'Major', 'Concomitant use of rivaroxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation inhibitors, other anticoagulants, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during rivaroxaban therapy may also be increased by the concomitant use of other drugs that affect coagulation. The development of epidural and spinal hematoma can lead to long-term neurological injury or permanent paralysis.', NULL, 'Caution is recommended if rivaroxaban must be used with other agents that alter hemostasis.', NULL, 'Caution is recommended if rivaroxaban must be used with other agents that alter hemostasis. Patients should be monitored for increased anticoagulant effects and bleeding complications. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426853, 'Rofecoxib', 'Naproxen', 'Moderate', 'Concomitant use of COX-2 inhibitors with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation. The risk is dependent on both dosage and duration of therapy.', NULL, 'The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided.', NULL, 'The use of COX-2 inhibitors with non-aspirin NSAIDs should be avoided. Some authorities consider the use of COX-2 inhibitors with non-aspirin NSAIDs as contraindicated.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426854, 'Rucaparib', 'Naproxen', 'Moderate', 'Coadministration with rucaparib may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of CYP450 1A2. The proposed mechanism is decreased clearance due to rucaparib-mediated inhibition of CYP450 1A2.', NULL, 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if rucaparib is used concomitantly with drugs that are substrates of CYP450 1A2, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever rucaparib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426855, 'Esomeprazole', 'Selpercatinib', 'Major', 'Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of selpercatinib and reduce its concentrations in plasma.', NULL, 'Concomitant use of selpercatinib with proton pump inhibitors should generally be avoided.', NULL, 'Concomitant use of selpercatinib with proton pump inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking selpercatinib with food to minimize the clinical impact of the interaction.', 'Absorption', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426856, 'Sertraline', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426857, 'Sibutramine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426858, 'Sirolimus', 'Naproxen', 'Major', 'Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426859, 'Sotalol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426860, 'Sparfloxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426861, 'Esomeprazole', 'St. John''s Wort', 'Moderate', 'Coadministration with potent inducers of CYP450 2C19 and/or 3A4 may significantly decrease the plasma concentrations of omeprazole, which is primarily metabolized by these isoenzymes.', NULL, 'The concomitant use of omeprazole or esomeprazole with St.', NULL, 'The concomitant use of omeprazole or esomeprazole with St. John''s wort or rifampin should generally be avoided.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426862, 'Streptokinase', 'Naproxen', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426863, 'Streptomycin', 'Naproxen', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426864, 'Sulfasalazine', 'Naproxen', 'Moderate', 'Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure.', NULL, 'Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', NULL, 'Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426865, 'Sulfinpyrazone', 'Naproxen', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426866, 'Sulindac', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426867, 'Tacrolimus', 'Naproxen', 'Major', 'Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426868, 'Telmisartan', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426869, 'Temsirolimus', 'Naproxen', 'Major', 'Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.', NULL, 'Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426870, 'Tenecteplase', 'Naproxen', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426871, 'Teriflunomide', 'Naproxen', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity including NSAIDs and salicylates may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide. Pharmacokinetically, the active metabolite of leflunomide has been shown to cause increases of 13% to 50% in the free fraction of diclofenac and ibuprofen. Additionally, in vitro studies indicate that the metabolite inhibits hepatic microsomal enzyme CYP450 2C9, which participates in the metabolism of many NSAIDs.', NULL, 'Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity.', NULL, 'Patients receiving leflunomide or teriflunomide in combination with NSAIDs should be closely monitored for hepatotoxicity. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times the upper limit of normal) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426872, 'Tioguanine', 'Naproxen', 'Moderate', 'The concomitant or sequential use of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with thioguanine. A high risk of liver toxicity characterized by vascular endothelial damage has been reported with long-term continuous use of thioguanine, particularly in children receiving the drug as part of maintenance therapy for acute lymphoblastic leukemia and in other conditions associated with continuous use.', NULL, 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when thioguanine is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Baseline and regular monitoring of hepatic function is recommended. Thioguanine therapy should be discontinued if there is evidence of toxic hepatitis or biliary stasis, as reversal of signs and symptoms of liver toxicity have been reported upon withdrawal. Early indications of liver toxicity are signs associated with portal hypertension such as thrombocytopenia out of proportion with neutropenia and splenomegaly. Elevations of liver enzymes have also been reported, but do not always occur.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426873, 'Ticlopidine', 'Naproxen', 'Moderate', 'Ticlopidine has been reported to potentiate the effect of nonsteroidal anti-inflammatory agents (NSAIDs) on platelet aggregation. The risk of bleeding may be increased, especially in patients with a history of gastrointestinal (GI) ulceration or bleeding.', NULL, 'Patients should be monitored for signs and symptoms of bleeding, especially GI bleeding, if NSAIDs and ticlopidine are coadministered.', NULL, 'Patients should be monitored for signs and symptoms of bleeding, especially GI bleeding, if NSAIDs and ticlopidine are coadministered. They should be advised to promptly report any signs of bleeding to their physician, including abdominal pain, vomiting blood, red or black stools, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, nosebleeds, bleeding of gums from brushing, red or brown urine, or other unusual bleeding or bruising. Patients should also be counseled to avoid any other over-the-counter NSAID products.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426874, 'Tiludronic acid', 'Naproxen', 'Moderate', 'Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs.', NULL, 'Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426875, 'Timolol', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of beta-blockers. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Indomethacin and piroxicam have been reported to have greater attenuating effects than other NSAIDs, and indomethacin effects may be significant in patients with eclampsia.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving a beta-blocker who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426876, 'Tinzaparin', 'Naproxen', 'Major', 'In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids.', NULL, 'Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426877, 'Tirofiban', 'Naproxen', 'Moderate', 'The risk of bleeding associated with glycoprotein IIb/IIIa inhibitors is increased in the presence of nonsteroidal anti-inflammatory agents due to additive inhibitory effects on platelet function. Arterial puncture sites may be most problematic.', NULL, 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.', NULL, 'It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426878, 'Tobramycin', 'Naproxen', 'Moderate', 'The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy.', NULL, 'Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426879, 'Tolazamide', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426880, 'Tolbutamide', 'Naproxen', 'Moderate', 'The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment.', NULL, 'Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426881, 'Tolmetin', 'Naproxen', 'Moderate', 'Concomitant use of more than one nonsteroidal anti-inflammatory drug (NSAID) at a time may increase the potential for serious gastrointestinal toxicity including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, or intestines. These events can occur at any time during NSAID use, with or without warning symptoms. The risk is dependent on both dosage and duration of therapy.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided.', NULL, 'Concomitant use of more than one NSAID at a time should generally be avoided. Patients treated with an NSAID should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, misoprostol, proton pump inhibitors) may be considered in high risk patients.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426882, 'Torasemide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426883, 'Tositumomab', 'Naproxen', 'Major', 'Coadministration of tositumomab and iodine I 131 tositumomab with drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Tositumomab and iodine I 131 tositumomab alone can cause severe or life-threatening thrombocytopenia.', NULL, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously.', NULL, 'Due to the frequent occurrence of severe and prolonged thrombocytopenia associated with tositumomab and iodine I 131 tositumomab, concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously. Close clinical and laboratory observation for bleeding complications is recommended during and after the therapeutic regimen.', 'Synergism', NULL, NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426884, 'Trandolapril', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of ACE inhibitors. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and ACE inhibitors may also cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible. Chronic use of NSAIDs alone may be associated with renal toxicities, including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving ACE inhibitors who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426885, 'Triamterene', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426886, 'Trichlormethiazide', 'Naproxen', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', NULL, 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426887, 'Trovafloxacin', 'Naproxen', 'Moderate', 'Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', NULL, 'Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426888, 'Urokinase', 'Naproxen', 'Moderate', 'Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426889, 'Valsartan', 'Naproxen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.', NULL, 'Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426890, 'Vancomycin', 'Naproxen', 'Moderate', 'When administered concomitantly, vancomycin and ketorolac may have additive nephrotoxic effects. Ketorolac, like other nonsteroidal anti-inflammatory drugs (NSAIDs), inhibits vasodilatory renal prostaglandin synthesis. In addition, chronic use of NSAIDs may also be associated with renal toxicities, including renal failure. The mechanism of vancomycin-induced nephrotoxicity is unknown; however, the risk may be increased in patients with preexisting risk factors for nephrotoxicity, high vancomycin blood levels, or prolonged treatment.', NULL, 'Caution is recommended in patients receiving ketorolac or other NSAIDs in combination with IV vancomycin, particularly in patients with preexisting risk factors for nephrotoxicity.', NULL, 'Caution is recommended in patients receiving ketorolac or other NSAIDs in combination with IV vancomycin, particularly in patients with preexisting risk factors for nephrotoxicity. Renal function and vancomycin therapeutic drug monitoring is recommended according to local policies and protocols. The dose and duration of concomitant NSAID therapy should also be minimized where possible.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426891, 'Vasopressin', 'Naproxen', 'Moderate', 'The antidiuretic response to vasopressin or desmopressin may be potentiated by certain drugs, including nonsteroidal anti-inflammatory agents, selective serotonin reuptake inhibitors, tricyclic/tetracyclic antidepressants, carbamazepine, chlorpropamide, chlorpromazine, clofibrate, eslicarbazepine, fludrocortisone, haloperidol, lamotrigine, oxcarbazepine, urea, and some antineoplastic agents (e.g., vinca alkaloids, cisplatin, cyclophosphamide). These drugs can occasionally cause fluid retention, in some cases secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Coadministration with vasopressin or desmopressin may, therefore, increase the risk of water intoxication and/or hyponatremia. Seizure and coma in association with severe hyponatremia have been reported during concomitant use of desmopressin and imipramine or ibuprofen.', NULL, 'Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH.', NULL, 'Caution is advised when vasopressin or desmopressin is used in combination with drugs that can cause fluid retention or SIADH. Some authorities recommend adjusting vasopressin dosage as needed. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek medical attention if they develop signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, unsteadiness (which may lead to falls), anuria, and weight gain. Severe hyponatremia can be life-threatening if it is not promptly diagnosed and treated; therefore, early treatment is important to help prevent progression to seizures, coma, respiratory arrest, and death.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426892, 'Venlafaxine', 'Naproxen', 'Moderate', 'Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis.', NULL, 'Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
INSERT OR IGNORE INTO drug_interactions (
        id, ingredient1, ingredient2, severity, effect, arabic_effect,
        recommendation, arabic_recommendation, management_text, mechanism_text,
        alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, updated_at
    ) VALUES (1426893, 'Verteporfin', 'Naproxen', 'Moderate', 'Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', 1767317476);
